Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom: A retrospective database study

International Journal of Clinical Practice

Volumn 65, Issue 7, 2011, Pages 797-806

  Kirby, M G ^a   Schnetzler, G ^b   Zou, K H ^c   Symonds, T ^d  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b Prism Ideas Ltd   (Switzerland)

^c PFIZER INC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; ERECTILE DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; PATIENT ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED KINGDOM; UROGENITAL TRACT DISEASE; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGONADISM; INCIDENTAL FINDINGS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79959325737     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02693.x     Document Type: Article

References (33)

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB,. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61. (Pubitemid 24046934)
2. Green JS, Holden ST, Ingram P, et al., An investigation of erectile dysfunction in Gwent, Wales. BJU Int 2001; 88: 551-3. (Pubitemid 34293796)
3. Nicolosi A, Laumann EO, Glasser DB, et al., Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology 2004; 64: 991-7. (Pubitemid 39469520)
4. NIH Consensus Development Panel on Impotence. Impotence-NIH Consensus Conference. JAMA 1993; 270: 83-90.
5. Gratzke C, Angulo J, Chitaley K, et al., Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med 2010; 7: 445-75.
6. McVary KT,. Clinical practice. Erectile dysfunction. N Engl J Med 2007; 357: 2472-81.
7. Goldstein I, Lue TF, Padma-Nathan H, et al., Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397-404. (Pubitemid 28221980)
8. Hackett G, Kell P, Ralph D, et al., British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med 2008; 5: 1841-65.
9. Hatzimouratidis K, Amar E, Eardley I, et al., Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010; 57: 804-14.
10. Montorsi F, Adaikan G, Becher E, et al., Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2010; 7: 3572-88.
11. Thompson IM, Tangen CM, Goodman PJ, et al., Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 2996-3002. (Pubitemid 41817661)
12. Hodges LD, Kirby M, Solanki J, O'Donnell J, Brodie DA,. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract 2007; 61: 2019-25. (Pubitemid 350077416)
13. Montorsi P, Ravagnani PM, Galli S, et al., The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol 2005; 96: 19M-23M. (Pubitemid 43017212)
14. Costa C, Virag R,. The endothelial-erectile dysfunction connection: an essential update. J Sex Med 2009; 6: 2390-404.
15. Jackson G, Montorsi P, Adams MA, et al., Cardiovascular aspects of sexual medicine. J Sex Med 2010; 7: 1608-26.
16. Tikkanen MJ, Jackson G, Tammela T, et al., Erectile dysfunction as a risk factor for coronary heart disease: implications for prevention. Int J Clin Pract 2007; 61: 265-8.
17. Kostis JB, Jackson G, Rosen R, et al., Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96: 313-21. (Pubitemid 40978596)
18. Hackett G,. The burden and extent of comorbid conditions in patients with erectile dysfunction. Int J Clin Pract 2009; 63: 1205-13.
19. Hatzichristou D, Hatzimouratidis K, Bekas M, et al., Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol 2002; 168: 615-20. (Pubitemid 34793308)
20. Solomon H, Man J, Wierzbicki AS, O'Brien T, Jackson G,. Erectile dysfunction: cardiovascular risk and the role of the cardiologist. Int J Clin Pract 2003; 57: 96-9. (Pubitemid 36372561)
21. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL,. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16: 393-401. (Pubitemid 46656860)
22. Kell PD, Hvidsten K, Morant SV, Harnett JP, Bridge S,. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK. BJU Int 2007; 99: 860-3. (Pubitemid 46439559)
23. Morant SV, Reilly K, Bloomfield GA, Chapple C,. Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK. Int J Clin Pract 2008; 62: 688-94. (Pubitemid 351533681)
24. Morant S, Bloomfield G, Vats V, Chapple C,. Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms. J Sex Med 2009; 6: 1103-10.
25. Wespes E, Amar E, Eardley I, et al., European Association of Urology Guidelines on Male Sexual Dysfunction: erectile dysfunction and premature ejaculation. March 2009; Available from: (accessed12 March 2010).
26. Fisher WA, Rosen RC, Eardley I, et al., The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction. J Sex Med 2004; 1: 150-60. (Pubitemid 40424648)
27. Kubin M, Wagner G, Fugl-Meyer AR,. Epidemiology of erectile dysfunction. Int J Impot Res 2003; 15: 63-71. (Pubitemid 36356360)
28. Schnetzler G, Banks I, Kirby M, Zou KH, Symonds T,. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors. J Sex Med 2010; 7: 1237-46.
29. Schnetzler G, Marfatia A, Zou KH, Muniain J, Symonds T,. Current erectile dysfunction management: a survey among delegates of the 2008 annual EAU congress in Milan. Eur Urol Suppl 2009; 8: 212 (Abstract 368).
30. Carey IM, Nightingale CM, DeWilde S, et al., Blood pressure recording bias during a period when the Quality and Outcomes Framework was introduced. J Hum Hypertens 2009; 23: 764-70.
31. Motheral B, Brooks J, Clark MA, et al., A checklist for retrospective database studies-Report of the ISPOR Task Force on Retrospective Databases. Value Health 2003; 6: 90-7. (Pubitemid 36403125)
32. Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P,. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010; 64: 240-55.
33. Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C,. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med 2009; 6: 658-74.